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Abstract
Malaria is a serious condition in the non-immune traveller, and prognosis depends on timely diagnosis. Although microscopy remains the
cornerstone of diagnosis, malaria rapid diagnostic tests (RDTs) are increasingly used in non-endemic settings. They are easy to use, provide results
rapidly and require no speciﬁc training and equipment. Reported sensitivities vary between different RDT products but are generally good for
Plasmodium falciparum, with RDTs detecting the P. falciparum antigen histidine-rich protein-2 (PfHRP2) scoring slightly better than P. falciparum-
lactate dehydrogenase (Pf-pLDH)-detecting RDTs. Sensitivity is lower for Plasmodium vivax (66.0 – 88.0%) and poor for Plasmodium ovale
(5.5 – 86.7%) and Plasmodium malariae (21.4 – 45.2%). Rapid diagnostic tests have several other limitations, including persistence of the PfHRP2
antigen, cross-reactions of P. falciparum with the non-falciparum test line and vice versa and (rare) false-positive reactions due to other infectious
agents or immunological factors. False-negative results occur in the case of low parasite densities, prozone effect or pfhrp2 gene deletions. In
addition, errors in interpretation occur, partly due to inadequacies in the instructions for use. Finally, RDTs do not give information about parasite
density. In the diagnostic laboratory, RDTs are a valuable adjunct to (but not a replacement for) microscopy for the diagnosis of malaria in the
returned traveller.In malaria endemic settings, special groups of travellers (those travelling for long periods, expatriates and short-stay
frequent travellers) who are remote from qualiﬁed medical services may beneﬁt from self-diagnosis by RDTs, provided they use correctly
stored RDT products of proven accuracy, with comprehensive instructions for use and appropriate hands-on training.
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Malaria in the Returned Traveller: a Serious
Condition with Difﬁcult Diagnosis
Yearly, approximately 10 000 cases of imported malaria are
reported, but the actual number may be as high as 30 000 [1].
Imported malaria is a potentially fatal condition and the
outcome depends largely on timely diagnosis and treatment
[2]. In malaria non-endemic settings, competence in the
microscopic diagnosis of malaria is often lacking because of
low exposure to malaria-positive samples [3]. Malaria rapid
diagnostic tests (RDTs) may be an alternative: RDTs are
simple, hand-held diagnostic devices that offer a quick (within
20 min) diagnosis. Results are visually read as coloured lines
on a strip, and no particular expertise is required.
Malaria Rapid Diagnostic Tests: Mechanism,
Target Antigens and Formats
Malaria RDTs consist of a nitrocellulose strip mostly embed-
ded in a plastic cassette; occasionally, this strip may present as
a dipstick (self-standing strip to be dipped in a tube) or be
enclosed in a cardboard format. The mechanism of action is
explained in Fig. 1.
The following antigens may be detected: histidine-rich
protein-2 (PfHRP2) and P. falciparum-speciﬁc parasite lactate
dehydrogenase (Pf-pLDH) (which are both speciﬁc for P. fal-
ciparum), P. vivax-pLDH (Pv-pLDH, speciﬁc to P. vivax) and
pan-pLDH and aldolase (common to all human Plasmodium
species). Malaria RDTs are categorized as two-, three- or
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four-band products, depending on the number of lines
(‘bands’) that may become visible on the strip, with the
control line standing for one band. Two-band RDTs detect a
single antigen (mostly PfHRP2), whereas three-band RDTs
detect P. falciparum (PfHRP2 or Pf-pLDH) and in addition
mostly a pan-malaria antigen (pan-pLDH or aldolase); four-
band RDTs detect a P. falciparum-speciﬁc antigen, a pan-
malaria antigen and a P. vivax-speciﬁc antigen (Fig. 2).
Key-points of the Laboratory Diagnosis of
Malaria in Returned Travellers
Microscopy represents the cornerstone of malaria diagnosis as it
provides all relevant information: conﬁrmation of the diagnosis
of malaria; species differentiation (which is important because
P. falciparum is life-threatening and because treatment is not the
FIG. 1. Schematic drawing of a malaria rapid diagnostic test. Sequence of events when performing an MRDT. Blood and buffer are applied,
respectively, to the sample and buffer pad. They are attracted by the capillary action of the absorption pad and start to migrate. First, they pass the
conjugate pad, which contains a detection antibody targeting a Plasmodium antigen, such as PfHRP2, Pf-pLDH, Pv-pLDH, pan-pLDH or aldolase (for
abbreviations see text). This detection antibody is a mouse-antibody that is conjugated to a signal, mostly colloidal gold. If present in the sample, the
Plasmodium antigen is bound to this detection antibody-conjugate. Next, the antigen-antibody-conjugate complex migrates further until it is bound to
the capture antibody, which binds to another site of the Plasmodium target antigen. As the capture antibody is applied on a narrow section of the
strip, the complex with the conjugated signal will be concentrated and by virtue of the colloidal gold will become visible as a coloured line. The excess
of detection antibody-conjugate that was not bound by the antigen and the capture antibody moves further until it is bound to a goat-raised anti-
mouse antibody, thereby generating a control line.
FIG. 2. Two-, three- and four-band malaria RDTs (above, middle and below, respectively) run with a P. falciparum sample (left) and a P. vivax sample
(right). The two-band RDT shows the control line and a P. falciparum (PfHRP2)-line for the P. falciparum sample and only a control line for the P. vivax
sample: correct reporting is ‘P. falciparum’ and ‘no P. falciparum detected’, respectively. The three-band RDT shows, apart from the control line,
PfHRP2 and pan-pLDH test lines for P. falciparum: correct reporting is ‘P. falciparum, mixed infection with non-falciparum species not excluded’. The
P. vivax sample shows only a pan-pLDH test line: correct reporting is ‘non-falciparum species’. For the P. falciparum sample, the four-band RDT shows
test lines for the pan-pLDH and PfHRP2 test lines: correct reporting is ‘P. falciparum, mixed infection with P. ovale/P. malariae not excluded’. For the
P. vivax sample, pan-pLDH and Pv-pLDH test lines are visible: correct reporting is ‘P. vivax, mixed infection with P. ovale/P. malariae not excluded’.
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same for each species [4]); and determination of parasite
density, expressed as the number of red blood cells (RBC)
infected with asexual parasites (trophozoites and schizontes)
per lL of blood. In addition, signs of severity (presence of
schizontes and pigment-loaded white blood cells in the case of
P. falciparum) can be observed. Of note, the detection limit of
expert microscopy is close to 50/lL, but for non-experienced
microscopists, it is up to ten-fold higher (i.e. 500/lL) [5].
What are the Diagnostic Characteristics of
Malaria RDTs in Returned Travellers?
Sensitivity of RDTs for P. falciparum diagnosis can reach 100%
depending on the product [6–9]. PfHRP2-detecting RDTs
generally perform better at low parasite densities compared
with Pf-pLDH-detecting RDTs [6,7,9], although this depends
on the RDT product [10]. For all RDT products evaluated in
our setting (with PCR as the reference method), sensitivity
was signiﬁcantly lower at parasite densities below 100/lL
(median 74.1%, range 9.1 – 88.5%) compared with >100/lL
(median 94.3%, range 77.4 – 98.1%) [6,7,9–12]. This is of
concern as non-immune travellers may be symptomatic below
this threshold [13]: at the Institute of Tropical Medicine (ITM),
10% of patients with P. falciparum infection presented with
parasite density below 100/lL (Table 1).
For P. vivax diagnosis, compiled sensitivity of the Binax
NOW kit has been calculated to be 68.9% [13]. At ITM, we
observed for other RDT products sensitivities ranging
between 66.0% and 88.0%, increasing to 77.4 – 97.2% at
parasite densities >500/lL [6,7,9,11,12,14,15]. However, as
approximately 10% of patients presenting at ITM had parasite
densities <500/lL (Table 1), RDTs will not reliably exclude the
presence of P. vivax. For P. ovale and P. malariae, diagnostic
sensitivities are much lower, ranging from 5.5% to 86.7% and
21.4% to 45.2%, respectively, with a sharp decline in sensitivity
at parasite densities below 500/lL [6,7,9,11,15]. Poor perfor-
mance in the detection of P. ovale and P. malariae may partly be
explained by the lower afﬁnity of some monoclonal antibodies
to these species [16,17].
Plasmodium knowlesi infections are rare in travel medicine.
There is no RDT product with a test line speciﬁc for
P. knowlesi, but the species may cross-react with pLDH
antibodies speciﬁc for P. falciparum and P. vivax [18]. For six
published imported cases of P. knowlesi, RDT results were
positive in only one patient [19–24].
Does a Positive RDT Result Indicate Malaria
Infection?
False-positive RDTs are rare [6,7,9–11,15] but there are no
prospective data on their frequency. Over the years 2008–
2011 at ITM, we observed false-positive test lines for both a
PfHRP2-detecting and a Pf-pLDH-detecting three-band RDT
product in 0.4% of samples when using PCR as the reference
method (results not published). There was an additional 0.8%
of false-positive PfHRP2 lines, which may in part be explained
by PfHRP2 persistence after a past P. falciparum infection:
PfHRP2 can persist in the blood for up to several weeks after
successful treatment due to a low clearance [13]. False-
positive RDT results in patients with no recent history of
malaria have been observed in patients with other infections
(e.g. dengue, hepatitis C, toxoplasmosis, tuberculosis and
schistosomiasis) or with circulating immunological factors (e.g.
rheumatoid factor and anti-nuclear antibodies) [7,25,26].
Malaria RDTs do not Quantify Parasite
Density
Rapid diagnostic tests are not designed to give an indication of
parasite density. A statistically positive correlation between
RDT line intensity and parasite density has been observed but
there was overlap between the line intensity categories (faint,
weak, medium and strong) [6,7,9]. For example, although
strong PfHRP2 line intensities mainly occurred at parasite
densities >100/lL, they were also present at lower parasite
densities as well as in samples with pure gametocytemia [6,9].
The presence of a single PfHRP2 test line was almost
TABLE 1. Distribution of parasite densities (asexual para-
sites/lL) per species for the 1495 Plasmodium-positive sam-
ples submitted to ITM for the period January 2000 to June
2012. Only the ﬁrst sample per patient was included and
samples with exclusively sexual parasites (gametocytes) were
excluded
Parasite density
(/lL) Number
Single infection, species
Mixed
infection†
P.
falciparum
P.
vivax
P.
ovale
P.
malariae
0–100 105 4 16 4 1
101–500 132 18 34 3 5
501–5 000 294 86 63 25 13
5 001–250 000 512 82 14 7 10
>250 000 66 1 0 0 0
Total 1109 191 127 39 29
Cumulative (%)
 100 9.5 2.1 12.6 10.3 3.4
>100 90.5 97.9 87.4 89.7 96.6
>500 78.6 88.5 60.6 82.1 79.3
>5 000 52.1 43.5 11 17.9 34.5
>250 000 6 0.5 0 0 0
†Mixed infections included P. falciparum infection with P. ovale (n = 15) or
P. malariae (n = 12) and P. malariae infection with P. ovale (n = 1) or P. vivax
(n = 1).
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exclusively found at low (<1 000/lL) parasite densities
[6,9,15,27] but it may also indicate PfHRP2 persistence after
treated P. falciparum infection.
Use of Malaria RDTs in Returned Travellers:
Extent and Quality
Two prospective studies performed in routine diagnostic
laboratories in the USA concluded that RDTs performed
equally as well as or even better than microscopy [28,29]. The
use of RDTs in travel medicine is also expanding [3,30], with
80.0% of laboratories declaring that RDTs had improved their
malaria diagnosis [3]. A proﬁciency test performed in Belgium
and Luxembourg [3] showed that analytical performance of
RDTs was excellent, but errors occurred in interpretation and
reporting. Part of these errors was traced to inadequacies in
the RDTs’ instructions for use and further study revealed
multiple shortcomings in packaging, labelling and instructions
of many RDT products, including CE-labelled ones [3,31].
Limitations of Malaria RDTs
Rapid diagnostic tests are not foolproof and errors may occur.
Apart from the lower sensitivity at low parasite densities
discussed above, there is the prozone effect: an absent or faint
test line due to an excess of antigens blocking the binding sites
of both detection and capture antibodies, hindering binding of
the antigen-detection antibody-conjugate complex to the
capture antibody, with failure of signal generation. PfHRP2-
detecting but not Pf-pLDH-detecting test lines are affected by
the prozone effect [32,33]. The prozone effect occurs rarely,
but the consequences of a false-negative result are serious, as
the diagnosis of malaria (in the case of two-band RDTs) and
P. falciparum infections (in the case of three-band RDTs) may
be missed. Further, although not yet reported in travel
medicine, P. falciparum isolates lacking the gene encoding for
PfHRP2 have been reported in the Peruvian Amazon, and
infections by these strains, which may cause symptomatic
disease [34], are not picked up by PfHRP2-detecting RDTs
[34,35]. Furthermore, cross-reactions of P. falciparum samples
with the P. vivax-pLDH line have been reported [36], as well as
cross-reactions of non-falciparum samples with the P. falcipa-
rum-speciﬁc test line [6,14,15,34].
What can be Done to Overcome the
Limitations of Malaria RDTs?
When the RDT result is negative and there is still suspicion of
malaria, repeat testing should be considered (Table 2). As in
the case of microscopy, repeat testing does not need to be
synchronized with a peak of fever [13] but can be performed
after 8–12 h for three consecutive times to rule out malaria
[37,38]. Conversely, false-negative results due to the prozone
effect cannot be corrected by repeat testing, but when
performing microscopy the diagnosis will not be missed as
high parasite densities will not be overlooked easily even by
non-experienced microscopists. For this reason, as well as for
assessing parasite density and signs of severity, we advocate
that RDTs should be used in conjunction with microscopy and
not as a substitute [3].
What is the Place of Malaria RDTs in the
Diagnostic Strategy?
As a complement to microscopy, malaria RDTs can be very
useful as they point to the diagnosis of malaria and the
TABLE 2. Role of malaria rapid diagnostic tests in the non-endemic setting
Requirements for malaria diagnosis Contribution of RDTs Comments
Timely conﬁrmation or exclusion of the
diagnosis of malaria with prompt
referral in case of doubt
Considerably helpful in the diagnosis
of P. falciparum malaria, moderately
for P. vivax and poorly for P. ovale
and P. malariae
Excellent sensitivity for P. falciparum >100 parasites/lL
False-negatives for P. falciparum at low parasite densities (<100/lL), occasionally above
Therefore, repeat after 8–12 h for three consecutive times to rule out malaria
Do not rule out malaria in a conﬁdent
way (microscopy needed as well)
Infections caused by P. falciparum with PfHRP2 gene deletions will not be picked up by
PfHRP2-detecting RDTs
Prozone effect is rare but occurs, only PfHRP2- detecting products are affected
Moderate (approx. 70%) sensitivity for the diagnosis of P. vivax and poor sensitivity
(30–50%) for the diagnosis of P. ovale and P. malariae
Distinction between P. falciparum
(possible life-threatening) and the
non-falciparum species
Of considerable help in the identiﬁcation
of P. falciparum
Mixed infections are rare but not excluded if P. falciparum- and pan-species antigen lines
are present
Assessment of parasite densities, in
particular recognition of critical values
(>2% of red blood cells infected)
Of no help Line intensities are indicative for parasite density but there is a very large overlap
Unique P. falciparum line with no pan-species line may point to low parasite density
(<1 000/lL)
Recognition of P. falciparum stages and
hemozoin pigment in white blood cells
Of no help
Follow-up of treatment (decline of
parasite density upon start of therapy)
Of no help PfHRP2 persists for weeks
pLDH, PfHRP2 and aldolase are released by gametocytes
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involvement of P. falciparum with a detection limit equal to or
below that of routine microscopy. Occasionally, the persis-
tence of PfHRP2 may be of help to make an a posteriori
diagnosis of malaria in a returned traveller who consults after
self-administered or empiric treatment for suspected malaria
abroad. RDTs have also been studied as a tool for bedside
diagnosis (‘point of care testing’, POC). However, one study
showed lower sensitivity of POC compared with laboratory
performance and quality and performance of POC testing
should be carefully assured [39].
Some Comments about Implementation of
RDTs
Most RDTs marketed for malaria diagnosis in returned
travellers are three-band RDTs [3], which are of help in
differentiating P. falciparum from the non-falciparum species.
Four-band products are used as well [3] but there are few
published data and one report mentioned moderate sensitiv-
ities, cross-reactions of Plasmodium spp. and an excess of lines
with faint or weak intensity [15]. Older RDTs (cardboard and
hybrid formats) are less easy to use than the more recently
released ‘one-step’ RDTs in cassette format, although differ-
ences were not signiﬁcant when surveyed in laboratory
settings [3]. The blood transfer devices supplied with the
RDT products (loop, pipette, inverted cup and straw) are small
and may be difﬁcult to manipulate [39,40]; this is why we are
using a standard transfer pipette. Regarding target antigens for
P. falciparum, there is a small preference for PfHRP2 over Pf-
pLDH-detecting RDT products due to the higher sensitivity at
low parasite densities of the former, which is frequently
observed in non-endemic settings (Table 1). An overview of
the diagnostic performance of most of the commercially
available RDT products can be found in reports of the World
Health Organization (WHO) and Foundation for Innovative
New Diagnostics RDT evaluation rounds [41–43].
Quality Assurance for RDTs in Laboratory
use
With regard to ISO 15189 validation and internal quality
control, most important is to adequately train laboratory staff,
particularly because they will only perform RDTs sporadically.
RDTs usually have a shelf life of 18 – 24 months, allowing
incidental use. Lot-to-lot variation is not uncommon [7,42–44]
and therefore it is of interest to monitor indicators over time,
such as (i) invalid test results (they should occur rarely, i.e.
<0.5%) [6,7,9–12,14,15,36], (ii) proportions of lines with weak
and faint line intensities and (iii) the occurrence of false-positive
and false-negative reactions. Validation of implementation
should consist of a small panel of samples of P. falciparum at
high (>1 000/lL) and low (100/lL) parasite densities, as well as a
few non-falciparum and Plasmodium-negative samples. In addi-
tion, regular proﬁciency testing should be organized, and active
post-marketing surveillance might trace lot-to-lot variations.
Use of RDTs for Self-diagnosis by Travellers
Travellers and expatriates staying for longer periods in malaria-
endemic settings are generally more prone to acquiring malaria
infection due to poor adherence to malaria prophylaxis
regimens [45,46]. Besides, they are facing particular problems
of malaria diagnosis, such as the absence of qualiﬁed medical
services in remote settings or the tendency to over-diagnose
malaria in local laboratories [47–49]. Therefore, the use of
self-administration of antimalarials, known as stand-by emer-
gency treatment (SBET), has been advocated for speciﬁc
groups of travellers, including long-term expatriates and short-
stay frequent travellers such as aircrews and business travel-
lers [1,50]. However, malaria recognition based on clinical
symptoms is difﬁcult, especially for the non-experienced
traveller, and will lead to an overuse of SBET [51]. Combining
SBET with a reliable rapid test could prevent its overuse. In the
1990s, use of malaria RDTs was suggested for self-diagnosis of
travellers [52].
Several studies on symptomatic travellers performing RDT
self-diagnosis revealed major errors in test manipulation
(ﬁnger prick, application of blood and adherence to the
reading time) and interpretation [53–57]. Thereafter RDTs
were only recommended for speciﬁc situations (e.g. long-term
stay, expats, rural areas) after appropriate instructions and
training [58]. A more recent evaluation of self-testing among
oilﬁeld service employees showed that RDTs can be useful for
expatriates when appropriate instructions are received [46].
In recent years, the design and user-friendliness of RDT
products have improved and RDTs for self-diagnosis are
currently advertised and sold through the internet [59]. We
recently evaluated a panel of RDTs marketed for self-diagnosis
and found large variations in diagnostic accuracy, as well as
poor quality of instructions for use [59]. Before marketing
these RDTs for the traveller, improvement of these instruc-
tions is needed as well as a comprehensive training programme
and follow-up of test results.
In our setting, we offer training on RDT self-diagnosis for
travellers referred by physicians during pre-travel consulta-
tions. Travellers are provided with a simple layman-directed
step-by-step description of the RDT product (www.labquality.be),
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which includes comments on limitations of RDTs and on what
to do with the test results (e.g. repeat testing in the case of a
negative result but persistence of symptoms). The training
comprises hands-on practice as well as a photo-based quiz
about RDT interpretation. Participants are further invited to
email photographs of the RDTs they performed on-site for
follow-up and advice. To facilitate ﬁnger pricking, we replaced
the simple ‘plain lancet’ provided in the RDT kit with a ‘safety
lancet’ (Sarstedt, N€umbrecht, Germany). Furthermore, we
provide extra safety lancets, alcohol wipes and transfer
devices, as repeat ﬁnger pricking and transfer attempts may
be expected. From our training sessions, we learned that
repeat hands-on practice is essential for acquiring dexterity in
ﬁnger pricking and transfer of blood; therefore we recommend
RDT self-testing only for those who have been trained or have
practised RDTs appropriately; it goes without saying that
stressful conditions may decrease the actual performance
(Fig. 3). RDTs for self-diagnosis may be useful for the traveller
when comprehensive instructions and a training programme
are guaranteed, but further study needs to assess their value
under ﬁeld settings.
Conclusion
Malaria RDTs are increasingly used in travel medicine. They
contribute to (i) the diagnosis of malaria and (ii) the detection
of P. falciparum. Their help in the diagnosis of malaria caused by
P. vivax and P. ovale/P. malariae is moderate and poor, respec-
tively. Moreover, RDTs do not provide data about parasite
density and they are subject to technical and procedural
errors. In view of their merits, affordable price and long shelf
life, RDTs have a place as a valuable adjunct to microscopy in
the laboratory diagnosis of malaria. For special groups of
travellers and expatriates not in reach of competent labora-
tory diagnosis, RDT self-diagnosis is of help, provided there is
use of a correctly stored RDT product of proven accuracy and
appropriate hands-on training.
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